cyrillebuhrmandirector.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): June 28,
2007
Commission
File No. 000-16929
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1101
Brickell Ave., Suite 701 S
Miami,
FL
|
|
33131
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(786)
425-3848
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 5.02. Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On
June 29, 2007, DOR BioPharma, Inc. (the “Company”) announced the
appointment of Cyrille F. Buhrman, to the Company’s Board of Directors. Mr.
Buhrman will serve on the Company’s Audit Committee, Nominating Committee and
Compensation Committee.
Mr.
Buhrman is Managing Director, Chairman and owner of Pacific Healthcare
(Thailand) Co., Ltd., a full service marketing, sales, distribution and
regulatory affairs company based in Thailand where he has served for
approximately ten years. Pacific Healthcare is currently expanding throughout
Southeast Asia, beginning with the Philippines and Vietnam this year. Mr.
Buhrman is a Director of Pacific Healthcare (Philippines) Inc., International
Pharmaceuticals Ltd., a company focused on marketing Specialty pharmaceutical
products in Thailand, Vision Care (Thailand) Co., Ltd, and Canyon
Pharmaceuticals, Inc., a private biotechnology company focused on the
commercialization of therapeutics to prevent and treat thrombosis and related
conditions. Mr. Buhrman is owner of Markle Holdings Ltd., an
investment fund specializing in biotech and pharmaceutical investments. Mr.
Buhrman is also one of DOR’s largest shareholders.
As
a new
Board member, the Company granted Mr. Buhrman options to purchase 150,000 shares
of the Company’s common stock at a strike price of $0.33 and an expiration date
of June 27, 2017.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
99.1 Press
release issued
by DOR BioPharma, Inc. on June 29, 2007.
SIGNATURE
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
DOR BIOPHARMA, INC.
By: /s/ Christopher J. Schaber
Name: Christopher J. Schaber
|
|
Title: Chief
Executive Officer
|
Date:
June 29, 2007